

Nivo/Ipi (nivolumab and ipilimumab) CheckMate 040

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



Nivo/Ipi (nivolumab and ipilimumab) CheckMate 040

### FINAL SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Patients with HCC who have been previously treated with sorafenib

Experimental Arm: Nivo/Ipi (nivolumab and ipilimumab)

Control Arm: Single arm (Phase II)

